Hunt Hazel 4

What Happened
Hunt Hazel, Corcept Therapeutics' Chief Scientific Officer, received a grant of 140,000 shares on February 27, 2026. The award is recorded as a derivative acquisition at a $0.00 price (i.e., an equity award rather than an open‑market purchase). This is a compensation/retention grant, not a sale or purchase of existing shares.

Key Details

• Transaction date: 2026-02-27; filing date: 2026-03-03 (filed within the normal two-business-day window).
• Award amount: 140,000 shares; acquisition price reported as $0.00 (derivative security).
• Shares owned after transaction: not disclosed in the filing.
• Vesting/exercise terms: award vests/exercises ratably in equal installments on each monthly anniversary of Feb 27, 2026 over a four‑year period, contingent on continued service (footnote F1).
• Administrative note: form signed under a power of attorney (per remarks).

Context
This was an equity compensation grant (derivative award), commonly used for executive retention and incentive. Because the award vests over time rather than representing an immediate market purchase or sale, it should be viewed as part of routine compensation rather than a direct trading signal.